We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Calliditas Therapeutics AB | NASDAQ:CALT | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.1601 | 0.73% | 22.19 | 18.40 | 23.35 | 22.19 | 21.79 | 21.79 | 754 | 22:16:11 |
STOCKHOLM, April 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 16/760,910 entitled "Use of NOX Inhibitors for Treatment of Cancer". This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
The allowed claims cover a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent, when issued, will have an anticipated expiration date in 2038.
"This is a significant value enhancing event for the global setanaxib franchise and we are delighted that we are able to expand product protection for setanaxib in the important area of oncology," said CEO Renée Aguiar-Lucander.
Calliditas has corresponding applications in several additional territories around the world, including a pending patent application in Europe.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on April 8, 2023, at 09:00 a.m. CET.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-receives-notice-of-allowance-for-united-states-patent-application-covering-setanaxib-in-c,c3957702
The following files are available for download:
https://mb.cision.com/Main/16574/3957702/2715464.pdf | Setanaxib Patent Press Release_ENG |
View original content:https://www.prnewswire.co.uk/news-releases/calliditas-receives-notice-of-allowance-for-united-states-patent-application-covering-setanaxib-in-cancer-treatment-302110166.html
Copyright 2024 PR Newswire
1 Year Calliditas Therapeutics AB Chart |
1 Month Calliditas Therapeutics AB Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions